A Phase III Study of an Otic Formulation in Acute Otitis Media With Tympanostomy Tubes

NCT ID: NCT00578474

Last Updated: 2012-12-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

911 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-12-31

Study Completion Date

2008-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine if an otic formulation is safe and effective in treating middle ear infections in patients with ear tubes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Otitis Media

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Acute otitis media Tympanostomy tubes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Moxidex

Moxidex otic solution

Group Type EXPERIMENTAL

Moxidex otic solution

Intervention Type DRUG

4 drops into the infected ear(s) twice daily (morning and evening) for 7 days

Tympanostomy tubes

Intervention Type DEVICE

Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children

FLOXIN

Ofloxacin otic solution

Group Type ACTIVE_COMPARATOR

Ofloxacin otic solution

Intervention Type DRUG

5 drops into the infected ear(s) twice daily (morning and evening) for 10 days

Tympanostomy tubes

Intervention Type DEVICE

Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Moxidex otic solution

4 drops into the infected ear(s) twice daily (morning and evening) for 7 days

Intervention Type DRUG

Ofloxacin otic solution

5 drops into the infected ear(s) twice daily (morning and evening) for 10 days

Intervention Type DRUG

Tympanostomy tubes

Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

FLOXIN

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 6 months to 12 years old
* Ear tubes in one or both ears
* Ear drainage visible by the parent / guardian
* Ear drainage less than 21 days
* Ear tube may not be silver oxide, silver salt, t-type tube or long-shafted tube
* Patient may not have non-tube otorrhea
* Patient may not have had otic surgery other than tube placement in the last year
* Patient may not be a menarchal female
* Diabetic patients are not eligible
* Patient may not have any disease or condition that would negatively affect the conduct of the study
* Patient may not require any other systemic antimicrobial therapy during the study
* Patient must meet certain medication washouts to be eligible
* Analgesic use (other than acetaminophen) is not allowed
* Patient may not be pre-disposed to neurosensory hearing loss

Exclusion Criteria

* Age related
Minimum Eligible Age

6 Months

Maximum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Alcon Research

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Contact Alcon Call Center

Role: STUDY_DIRECTOR

1-888-451-3937

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

C-05-35

Identifier Type: -

Identifier Source: org_study_id